Separated serum was used for the analysisCombined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India.
Mohana Kumari ChidanandaDeepy ZohmangaihiSant RamShiv Lal SoniVikas SuriPankaj MalhotraRavjit Singh JassalJyotdeep KaurIndu VermaSadhna SharmaPublished in: Indian journal of clinical biochemistry : IJCB (2021)
Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological response in relation to age, gender, time period and severity of disease, Roche Elecsys anti-SARS-CoV-2 test was used which analysed both IgM and IgG. One hundred and three COVID-19 patients were enrolled. Seropositivity was seen in 64% of patients, with 33% at ≤ 7 days, 62% between 8 and 15 days and 81% at ≥ 16 days from the time of admission. Men (65%) showed higher antibody response than women (59%), whereas no difference was observed in seropositivity with respect to age of the patients. Dynamics of antibody responses revealed individual variations. Patients in ICU had higher antibody reactivity with 67% positivity as compared to 60% positivity in non-ICU patients. Kinetics of antibody response during COVID-19 disease varied in relation to gender, age, time period and severity and these factors might play an important role in treatment and control of COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- emergency department
- intensive care unit
- pregnant women
- mental health
- skeletal muscle
- polycystic ovary syndrome
- middle aged
- combination therapy